person · Reporting owner

Belldegrun Arie

Disclosed activity across 6 companies

Tapewire entity: 35650
SEC CIK: 0001296549

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Allogene Therapeutics, Inc.ALLO · Entity 5243	Director	February 02, 2026	February 04, 2026
Ginkgo Bioworks Holdings, Inc.DNA · Entity 5530	Director	June 12, 2024	June 14, 2024
UroGen Pharma Ltd.URGN · Entity 4466	Director	June 22, 2026	June 24, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Allogene Therapeutics, Inc.

Report date February 02, 2026 · Filed February 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.87 · Expires 2036-02-02	Direct	929,913	Reported balance After 2026-02-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-02-02 · Grant · Acquired 929,913 · Balance 929,913 F5: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	263,033	Reported balance After 2026-02-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-02-02 · Grant · Acquired 263,033 · Balance 263,033 F6: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,710,120	Reported balance Holding disclosure · report date 2026-02-02 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,710,120 F1: The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,798,163	Reported balance Holding disclosure · report date 2026-02-02 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,798,163 F2: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,724,137	Reported balance Holding disclosure · report date 2026-02-02 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 1,724,137 F3: The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	539,867	Reported balance Holding disclosure · report date 2026-02-02 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 539,867 F4: The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
Common StockSEC Table I · non-derivative	Direct	2,236,816	Reported balance Holding disclosure · report date 2026-02-02 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 2,236,816

Filing footnotes · ownership attribution and instrument terms

F1: The securities are held in the name of Bellco Legacy Trust fbo Rebecka Belldegrun, of which the reporting person's spouse is trustee and beneficiary

F2: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. There porting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.

F5: 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

F6: Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date.

Ginkgo Bioworks Holdings, Inc.

Report date June 12, 2024 · Filed June 14, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	194,925	Reported balance After 2024-06-12 transaction · row 1 1 source row Row 1 · 2024-06-12 · Exercise / conversion · Acquired 105,263 · Balance 194,925 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2024-06-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-06-12 · Exercise / conversion · Disposed 105,263 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	432,900	Reported balance After 2024-06-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-06-13 · Grant · Acquired 432,900 · Balance 432,900 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2034-06-13	Direct	571,428	Reported balance After 2024-06-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-06-13 · Grant · Acquired 571,428 · Balance 571,428 F5: In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000. F4: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.
Class A Common StockSEC Table I · non-derivative	IndirectBy Bellco Legacy LLC	500,000	Reported balance Holding disclosure · report date 2024-06-12 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 500,000 F2: Bellco Legacy LLC is owned and managed by trusts controlled by the Reporting Person and Rebecka Belldegrun.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

F2: Bellco Legacy LLC is owned and managed by trusts controlled by the Reporting Person and Rebecka Belldegrun.

F3: In accordance with the Issuer's Non-Employee Director Compensation Program, the RSUs granted on June 16, 2023 vested in full in Class A shares on June 12, 2024, which was the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, and was subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date.

F4: The vesting date of the RSUs and stock options, and in the case of the stock options the date they become exercisable, will be the earlier of (i) June 13, 2025 or (ii) the day immediately prior to the date of the Issuer's next Annual Meeting of Shareholders occurring after the grant date, in either case subject to the Reporting Person continuing in service as a Non-Employee Director of the Issuer through such date. The RSUs have no expiration date.

F5: In accordance with the Issuer's Non-Employee Director Compensation Program, the Black-Scholes value of the option award as of the grant date is $200,000.

UroGen Pharma Ltd.

Report date June 22, 2026 · Filed June 24, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.99 · Expires 2036-06-22	Direct	20,000	Reported balance After 2026-06-22 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-22 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Kite Pharma, Inc.

Report date September 25, 2017 · Filed October 06, 2017

Section 16 reporting ended · disclosed 2017-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2017-10-03 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2017-09-25 · Grant · Acquired 50,000 · Balance 159,160 Row 2 · 2017-10-03 · Disposition to issuer · Disposed 159,160 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3: Includes 114,950 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2017-10-03 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2017-10-03 · Disposition to issuer · Disposed 1,607,750 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5: The securities are held in the name of Arie and Rebecka Belldegrun as Trustees of the Belldegrun Family Trust dated February 18, 1994.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2017-10-03 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2017-10-03 · Disposition to issuer · Disposed 159,329 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6: The securities are held in the name of The Arie Belldegrun MD, Inc. Profit Sharing Plan, for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2017-10-03 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 5 · 2017-10-03 · Disposition to issuer · Disposed 430,190 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F7: The securities are held in the name of MDRB Partnership, L.P., of which the reporting person is a managing partner. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2017-10-03 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 6 · 2017-10-03 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F8: The securities are held in the name of Bioeast, LLC, of which the reporting person is a managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Common StockSEC Table I · non-derivative	IndirectSee footnote	Reported balance After 2017-10-03 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 7 · 2017-10-03 · Disposition to issuer · Disposed 500,000 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F9: The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the Manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23	Direct	Reported balance After 2017-10-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2017-10-03 · Disposition to issuer · Disposed 95,700 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F11: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F10: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.96 · Expires 2024-12-23	Direct	Reported balance After 2017-10-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2017-10-03 · Disposition to issuer · Disposed 43,500 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F12: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16	Direct	Reported balance After 2017-10-03 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2017-10-03 · Disposition to issuer · Disposed 44,057 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F11: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F13: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.87 · Expires 2025-12-16	Direct	Reported balance After 2017-10-03 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2017-10-03 · Disposition to issuer · Disposed 56,643 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F12: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F13: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.42 · Expires 2026-12-17	Direct	Reported balance After 2017-10-03 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2017-10-03 · Disposition to issuer · Disposed 159,700 · Balance 0 F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F12: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F14: This option provides for 25% vesting on December 27, 2017, and vesting thereafter in 36 equal monthly installments.

Filing footnotes · ownership attribution and instrument terms

F1: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.

F2: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes.

F3: Includes 114,950 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person.

F4: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio").

F5: The securities are held in the name of Arie and Rebecka Belldegrun as Trustees of the Belldegrun Family Trust dated February 18, 1994.

F6: The securities are held in the name of The Arie Belldegrun MD, Inc. Profit Sharing Plan, for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F7: The securities are held in the name of MDRB Partnership, L.P., of which the reporting person is a managing partner. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F8: The securities are held in the name of Bioeast, LLC, of which the reporting person is a managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F9: The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the Manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F10: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments.

F11: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option.

F12: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio.

F13: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments.

F14: This option provides for 25% vesting on December 27, 2017, and vesting thereafter in 36 equal monthly installments.

Kronos Bio, Inc.

Report date June 20, 2025 · Filed June 20, 2025

Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures, LLC	Reported balance After 2025-06-20 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2025-06-20 · Other · Disposed 2,765,314 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Common StockSEC Table I · non-derivative	IndirectBy Bellco Legacy II Trust	Reported balance After 2025-06-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2025-06-20 · Other · Disposed 679,575 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2031-06-21	Direct	Reported balance After 2025-06-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-06-20 · Disposition to issuer · Disposed 20,600 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-06-21	Direct	Reported balance After 2025-06-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21	Direct	Reported balance After 2025-06-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2034-06-24	Direct	Reported balance After 2025-06-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]

F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.

LB PHARMACEUTICALS INC

Report date September 12, 2025 · Filed September 16, 2025

Jointly reported with Vida Ventures GP III, L.L.C., Vida Ventures III, L.P., Vida Ventures III-A, L.P., Vida Ventures Management Co. LLC

Section 16 reporting ended · disclosed 2025-09-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures III, L.P.	880,214	Last balance in matching sequence After 2025-09-12 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2025-09-12 · Conversion · Acquired 547,648 · Balance 547,648 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 3 · 2025-09-12 · Purchase · Acquired 332,566 · Balance 880,214 F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures III-A, L.P.	2,029	Last balance in matching sequence After 2025-09-12 transaction · row 4 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2025-09-12 · Conversion · Acquired 1,262 · Balance 1,262 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any. Row 4 · 2025-09-12 · Purchase · Acquired 767 · Balance 2,029 F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Vida Ventures III, L.P.	0	Reported balance After 2025-09-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-09-12 · Conversion · Disposed 13,302,666 · Balance 0 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee"). F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectBy Vida Ventures III-A, L.P.	0	Reported balance After 2025-09-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-09-12 · Conversion · Disposed 30,667 · Balance 0 F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering. F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectBy Vida Ventures Management Co. LLC	1,434	Reported balance Holding disclosure · report date 2025-09-12 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 1,434 F5: These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series C Preferred Stock has no expiration date and converted automatically into Common Stock immediately prior to the Issuer's initial public offering at a conversion ratio based upon the initial price per share to the public in the Issuer's initial public offering.

F2: These shares are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III and may be deemed to have voting, investment, and dispositive power with respect to these securities. Arie Belldegrun, Helen Kim and Rajul Jain, are the members of the investment committee of Vida III GP (each, an "Investment Committee Member" and such committee, the "Investment Committee").

F3: (Continued from Footnote 2) The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

F4: These shares are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A and may be deemed to have voting, investment, and dispositive power with respect to these securities. The Investment Committee and each of the Investment Committee Members may be deemed to share voting, investment and dispositive power with respect to these securities. Vida III GP, the Investment Committee and each of the Investment Committee Members disclaims beneficial ownership of the securities held of record by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

F5: These shares are held directly by Vida Ventures Management Co., LLC ("Vida Management"). Each Investment Committee Member (as defined below) disclaims beneficial ownership of the securities held of record by Vida Management, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 24, 2021 Filed May 25, 2021 12:00 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	Exercise / conversionStock Option (Right to Buy) · Derivative	379,066	$0.00 Strike: $18.22	$0.00	Disclosure SEC source: 0001214659-21-005878 · marketforms-52924.xml · derivative · entry 6 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 379,066 shares Expires 2030-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
May 24, 2021 Filed May 25, 2021 12:00 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	Exercise / conversionCommon Stock	379,066	$18.22	$6,906,582.52	Disclosure SEC source: 0001214659-21-005878 · marketforms-52924.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 26, 2021 Filed Mar 30, 2021 21:00 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	199,223	$0.00 Strike: $33.78	$0.00	Disclosure SEC source: 0001214659-21-003612 · marketforms-52129.xml · derivative · entry 6 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,223 Underlying: Common Stock · 199,223 shares Expires 2031-03-26 F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2022, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
March 26, 2021 Filed Mar 30, 2021 21:00 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	53,635	$0.00	$0.00	Disclosure SEC source: 0001214659-21-003612 · marketforms-52129.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,968 Read SEC document
March 26, 2021 Filed Jun 9, 2021 17:47 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionStock Option (right to buy) · Derivative	3,241	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001209191-21-039138 · doc4a.xml · derivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,241 shares Expires 2021-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021. Read SEC document
March 26, 2021 Filed Jun 9, 2021 17:47 UTC Amendment	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	3,241	$5.00	$16,205.00	Disclosure SEC source: 0001209191-21-039138 · doc4a.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: On April 22, 2021, the reporting person filed a Form 4 that mistakenly listed the transaction date as March 24, 2021. Read SEC document
March 24, 2021 Filed Apr 22, 2021 21:19 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionStock Option (right to buy) · Derivative	3,241	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001209191-21-027978 · doc4.xml · derivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,241 shares Expires 2021-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 24, 2021 Filed Apr 22, 2021 21:19 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	3,241	$5.00	$16,205.00	Disclosure SEC source: 0001209191-21-027978 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionConvertible Promissory Note · Derivative	Not disclosed	$0.00 Strike: $16.15	$4,090,015.57	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · derivative · entry 10 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 253,251 shares Expires 2022-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F3 · ownership.nature: VV Manager LLC is the manager of Vida Ventures, LLC ("Vida"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries A Preferred Stock · Derivative	1,304,563	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · derivative · entry 9 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 1,376,313 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: VV Manager LLC is the manager of Vida Ventures, LLC ("Vida"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries Seed Preferred Stock · Derivative	650,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · derivative · entry 8 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 0 Underlying: Common Stock · 685,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: VV Manager LLC is the manager of Vida Ventures, LLC ("Vida"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries A Preferred Stock · Derivative	228,315	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · derivative · entry 7 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Bellco Legacy II Trust Disclosed balance after: 0 Underlying: Common Stock · 240,872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person currently serves as the trustee of Bellco Legacy II Trust ("Bellco"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionSeries Seed Preferred Stock · Derivative	173,333	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · derivative · entry 6 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Bellco Legacy II Trust Disclosed balance after: 0 Underlying: Common Stock · 182,866 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person currently serves as the trustee of Bellco Legacy II Trust ("Bellco"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	253,251	$16.15	$4,090,003.65	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · nonDerivative · entry 5 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 2,315,314 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: VV Manager LLC is the manager of Vida Ventures, LLC ("Vida"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	1,376,313	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · nonDerivative · entry 4 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 2,062,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F3 · ownership.nature: VV Manager LLC is the manager of Vida Ventures, LLC ("Vida"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	685,750	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · nonDerivative · entry 3 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Vida Ventures, LLC Disclosed balance after: 685,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F3 · ownership.nature: VV Manager LLC is the manager of Vida Ventures, LLC ("Vida"). The Reporting Person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the securities held by Vida. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	240,872	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Bellco Legacy II Trust Disclosed balance after: 679,575 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person currently serves as the trustee of Bellco Legacy II Trust ("Bellco"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco. Read SEC document
October 14, 2020 Filed Oct 16, 2020 19:44 UTC	Kronos Bio, Inc. KRON · Entity 78257	ConversionCommon Stock	182,866	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-055038 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Bellco Legacy II Trust Disclosed balance after: 438,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: The reporting person currently serves as the trustee of Bellco Legacy II Trust ("Bellco"). His wife, Dr. Rebecka Belldegrun, is the beneficiary of Bellco. Read SEC document
June 08, 2020 Filed Jun 10, 2020 22:35 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $28.24	$0.00	Disclosure SEC source: 0001209191-20-035676 · doc4.xml · derivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of one year. Read SEC document
June 04, 2020 Filed Jun 4, 2020 20:04 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	PurchaseCommon Stock	106,382	$47.00	$4,999,954.00	Disclosure SEC source: 0001214659-20-005383 · marketforms-48964.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,798,163 F2 · ownership.nature: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
June 04, 2020 Filed Jun 4, 2020 20:04 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	PurchaseCommon Stock	40,000	$47.00	$1,880,000.00	Disclosure SEC source: 0001214659-20-005383 · marketforms-48964.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 40,000 F1 · ownership.nature: The securities are held in the name of Bellco Legacy LLC (Bellco Legacy). Bellco Legacy is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun. Read SEC document
March 18, 2020 Filed Mar 20, 2020 20:38 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	379,066	$0.00 Strike: $18.22	$0.00	Disclosure SEC source: 0001214659-20-002807 · marketforms-48389.xml · derivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,066 Underlying: Common Stock · 379,066 shares Expires 2030-03-17 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
June 03, 2019 Filed Jun 5, 2019 20:52 UTC	UroGen Pharma Ltd. URGN · Entity 4466	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $34.83	$0.00	Disclosure SEC source: 0001209191-19-034777 · doc4.xml · derivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2029-06-02 F1 · derivative.exercise_date: The shares underlying the stock option will vest in equal quarterly installments over a period of two years. Read SEC document
May 13, 2019 Filed May 15, 2019 21:10 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	OtherCommon Stock	13,413	$0.00	$0.00	Disclosure SEC source: 0001209191-19-030079 · doc4.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 515,076 F3 · kind: The shares were received in the pro rata distribution from VVAG described above. F4 · ownership.nature: The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
May 13, 2019 Filed May 15, 2019 21:10 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	OtherCommon Stock	598,935	$0.00	$0.00	Disclosure SEC source: 0001209191-19-030079 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,791,480 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: The securities are held by VVAG, of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
April 26, 2019 Filed Apr 30, 2019 23:21 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	OtherCommon Stock	13,413	$0.00	$0.00	Disclosure SEC source: 0001209191-19-026675 · doc4.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 501,663 F3 · kind: The shares were received in the pro rata distribution from VVAG described above. F4 · ownership.nature: The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
April 26, 2019 Filed Apr 30, 2019 23:21 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	OtherCommon Stock	598,937	$0.00	$0.00	Disclosure SEC source: 0001209191-19-026675 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,390,415 F1 · kind: Pro rata distribution of shares of the Issuer's common stock from VVAG Special Fund LLC (VVAG) to its members pursuant to a Rule 10b5-1 trading plan adopted by VVAG on March 29, 2019. F2 · ownership.nature: The securities are held by VVAG, of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
March 27, 2019 Filed Mar 28, 2019 20:52 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionStock Option (right to buy · Derivative	128,000	$4.02 Strike: $4.02	$514,560.00	Disclosure SEC source: 0001209191-19-021635 · doc4.xml · derivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 128,000 shares Expires 2019-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares underlying the stock option vested on each of October 13, 2012, October 13, 2013, October 13, 2014 and October 13, 2015. Read SEC document
March 27, 2019 Filed Mar 28, 2019 20:52 UTC	UroGen Pharma Ltd. URGN · Entity 4466	Exercise / conversionOrdinary Shares	128,000	$4.02	$514,560.00	Disclosure SEC source: 0001209191-19-021635 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 13, 2019 Filed Mar 15, 2019 21:20 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantStock Option (Right to Buy) · Derivative	195,133	$0.00 Strike: $26.89	$0.00	Disclosure SEC source: 0001209191-19-019758 · doc4.xml · derivative · entry 6 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,133 Underlying: Common Stock · 195,133 shares Expires 2029-03-12 F5 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document
March 13, 2019 Filed Mar 15, 2019 21:20 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	GrantCommon Stock	115,333	$0.00	$0.00	Disclosure SEC source: 0001209191-19-019758 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,333 Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionSeries A Convertible Preferred Stock · Derivative	285,207	$0.00	$0.00	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · derivative · entry 8 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,497,336 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionSeries A Convertible Preferred Stock · Derivative	1,140,829	$0.00	$0.00	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · derivative · entry 7 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 5,989,352 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities are held by VVAG Special Fund LLC (VVAG), of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionSeries A Convertible Preferred Stock · Derivative	27,095	$0.00	$0.00	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · derivative · entry 6 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 142,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The securities are held in the name of the Belldegrun Family Trust. Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionCommon Stock	1,497,336	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · nonDerivative · entry 4 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,497,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionCommon Stock	5,989,352	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · nonDerivative · entry 3 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,989,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities are held by VVAG Special Fund LLC (VVAG), of which VVAG LLC is the manager. The reporting person is a Senior Managing Director of VVAG LLC and may therefore be deemed to be the beneficial owner of the common shares held by VVAG. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	ConversionCommon Stock	142,248	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,710,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into 5.25 shares of Common Stock upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The securities are held in the name of the Belldegrun Family Trust. Read SEC document
October 15, 2018 Filed Oct 17, 2018 21:29 UTC	Allogene Therapeutics, Inc. ALLO · Entity 5243	PurchaseCommon Stock	35,000	$18.00	$630,000.00	Disclosure SEC source: 0001209191-18-055372 · doc4.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Read SEC document
October 15, 2018 Filed Feb 13, 2019 22:10 UTC Amendment	Allogene Therapeutics, Inc. ALLO · Entity 5243	PurchaseCommon Stock	194,445	$18.00	$3,500,010.00	Disclosure SEC source: 0001209191-19-009724 · doc4a.xml · nonDerivative · entry 1 Belldegrun Arie · CIK 0001296549 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,691,781 F1 · kind: This transaction was inadvertently omitted from the reporting person's Form 4 filed October 17, 2018. F2 · ownership.nature: The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	159,700	Not disclosed Strike: $47.42	Not disclosed	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · derivative · entry 12 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 159,700 shares Expires 2026-12-17 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F12 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F14 · derivative.exercise_date: This option provides for 25% vesting on December 27, 2017, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	56,643	Not disclosed Strike: $63.87	Not disclosed	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · derivative · entry 11 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,643 shares Expires 2025-12-16 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F12 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F13 · derivative.exercise_date: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	44,057	$116.13 Strike: $63.87	$5,116,339.41	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · derivative · entry 10 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,057 shares Expires 2025-12-16 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F11 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F13 · derivative.exercise_date: This option provided for 25% vesting on December 17, 2016, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	43,500	Not disclosed Strike: $51.96	Not disclosed	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · derivative · entry 9 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,500 shares Expires 2024-12-23 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F12 · price: Pursuant to the terms of the Merger Agreement, each option to purchase Company common stock (each, a "Company Option") then outstanding and unexercised, other than any vested in-the-money Company Option, was assumed and converted into an option to purchase a number of shares of Parent common stock, on the same terms and subject to the same conditions as were applicable to such Company Option, equal to the product of (i) the total number of shares of Company common stock subject to such Company Option multiplied by (ii) the Equity Award Conversion Ratio, and with an exercise price equal to the quotient of (i) the exercise price of such Company Option divided by (ii) the Equity Award Conversion Ratio. F10 · derivative.exercise_date: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	95,700	$128.04 Strike: $51.96	$12,253,428.00	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · derivative · entry 8 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 95,700 shares Expires 2024-12-23 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F11 · price: This vested option was cancelled at the effective time of the Merger in exchange for a cash payment equal to the per-share merger consideration, less the exercise price of the option. F10 · derivative.exercise_date: This option provided for 25% vesting on December 24, 2015, and vesting thereafter in 36 equal monthly installments. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	500,000	$180.00	$90,000,000.00	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · nonDerivative · entry 7 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F9 · ownership.nature: The securities are held in the name of Bellco Capital, LLC, of which the reporting person is the Manager. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	500,000	$180.00	$90,000,000.00	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · nonDerivative · entry 6 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F8 · ownership.nature: The securities are held in the name of Bioeast, LLC, of which the reporting person is a managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	430,190	$180.00	$77,434,200.00	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · nonDerivative · entry 5 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F7 · ownership.nature: The securities are held in the name of MDRB Partnership, L.P., of which the reporting person is a managing partner. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	159,329	$180.00	$28,679,220.00	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · nonDerivative · entry 4 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F6 · ownership.nature: The securities are held in the name of The Arie Belldegrun MD, Inc. Profit Sharing Plan, for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	1,607,750	$180.00	$289,395,000.00	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · nonDerivative · entry 3 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F5 · ownership.nature: The securities are held in the name of Arie and Rebecka Belldegrun as Trustees of the Belldegrun Family Trust dated February 18, 1994. Read SEC document
October 03, 2017 Filed Oct 6, 2017 00:10 UTC	Kite Pharma, Inc. KITE · Entity 172664	Disposition to issuerCommon Stock	159,160	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-056215 · doc4.xml · nonDerivative · entry 2 Belldegrun Arie · CIK 0001296549 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On August 27, 2017, Kite Pharma, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Gilead Sciences, Inc., a Delaware corporation ("Parent"), and Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). On October 3, 2017, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F3 · shares: Includes 114,950 shares of Company common stock underlying restricted stock units with respect to Company common stock, including all time-vesting and all performance-vesting restricted stock units (each a "Company Restricted Stock Unit"), held by the Reporting Person. F4 · shares: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). F2 · price: Pursuant to the terms of the Merger Agreement, each share of Company common stock, other than the shares described in Notes 3 and 4 below, was converted into the right to receive an amount in cash equal to $180.00 (the "per-share merger consideration"), without interest and subject to any required withholding of taxes. F4 · price: Pursuant to the terms of the Merger Agreement, each Company Restricted Stock Unit was assumed and converted into a restricted stock unit denominated in shares of Parent common stock, on the same terms and conditions as were then applicable under such Company Restricted Stock Unit (including applicable performance vesting conditions), and relating to a number of shares of Parent common stock equal to the product of (i) the total number of shares of Company common stock subject to such Company Restricted Stock Unit multiplied by (ii) the quotient of (A) $180.00 divided by (B) the volume-weighted average closing sale price of a share of Parent common stock for the fifteen full consecutive trading days ending on and including September 28, 2017 ($83.12) (such quotient, the "Equity Award Conversion Ratio"). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.